These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29395795)

  • 41. [18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning.
    Travaini LL; Petralia G; Trifirò G; Ravasi L; Galetta D; Carbone G; Falcini F; Spaggiari L; Bellomi M; Paganelli G
    Lung Cancer; 2008 Sep; 61(3):362-8. PubMed ID: 18358558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole-body MRI versus an [
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [
    Jannusch K; Morawitz J; Schweiger B; Weiss D; Schimmöller L; Minko P; Herrmann K; Fendler WP; Quick HH; Antoch G; Umutlu L; Kirchner J; Bruckmann NM
    Eur Radiol; 2023 Nov; 33(11):8366-8375. PubMed ID: 37338559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The utility of FDG-PET in the diagnosis of thymic epithelial tumors.
    Otsuka H
    J Med Invest; 2012; 59(3-4):225-34. PubMed ID: 23037192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
    El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies.
    Benveniste MF; Moran CA; Mawlawi O; Fox PS; Swisher SG; Munden RF; Marom EM
    J Thorac Oncol; 2013 Apr; 8(4):502-10. PubMed ID: 23446204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
    Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Head and neck MRI-based T stage and [
    Xie HJ; Sun XS; Zhang X; Xiao BB; Lin DF; Lin XP; Lv XF; Liu LZ; Han F; Zou RH; Li JB; Fan W; Chen QY; Mai HQ; Tang LQ
    Eur Radiol; 2023 Nov; 33(11):7952-7966. PubMed ID: 37314471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
    Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
    Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Kaji Y; Fukasawa I; Inaba N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1912-20. PubMed ID: 18682935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of [
    Civan C; Ozkan ZG; Ozkan B; Isik EG; Erdogdu E; Has Simsek D; Duman S; Sanli Y; Kara M; Kuyumcu S; Toker A
    Cancer Biother Radiopharm; 2024 Jun; 39(5):373-380. PubMed ID: 38484307
    [No Abstract]   [Full Text] [Related]  

  • 58. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.